Design and activity of AP endonuclease-1 inhibitors

Apurinic/apyrimidinic endonuclease-1/redox effector factor-1 (APE-1) is a critical component of base excision repair that excises abasic lesions created enzymatically by the action of DNA glycosylases on modified bases and non-enzymatically by hydrolytic depurination/depyrimidination of nucleobases. Many anticancer drugs generate DNA adducts that are processed by base excision repair, and tumor resistance is frequently associated with enhanced APE-1 expression. Accordingly, APE-1 is a potential therapeutic target to treat cancer. Using computational approaches and the high resolution structure of APE-1, we developed a 5-point pharmacophore model for APE-1 small molecule inhibitors. One of the nM APE-1 inhibitors (AJAY-4) that was identified based on this model exhibited an overall median growth inhibition (GI50) of 4.19 μM in the NCI-60 cell line panel. The mechanism of action is shown to be related to the buildup of abasic sites that cause PARP activation and PARP cleavage, and the activation of caspase-3 and caspase-7, which is consistent with cell death by apoptosis. In a drug combination growth inhibition screen conducted in 10 randomly selected NCI-60 cell lines and with 20 clinically used non-genotoxic anticancer drugs, a synergy was flagged in the SK-MEL-5 melanoma cell line exposed to combinations of vemurafenib, which targets melanoma cells with V600E mutated BRAF, and AJAY-4, our most potent APE-1 inhibitor. The synergy between AJAY-4 and vemurafenib was not observed in cell lines expressing wild-type B-Raf protein. This synergistic combination may provide a solution to the resistance that develops in tumors treated with B-Raf-targeting drugs.

[1]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[2]  J. Sung,et al.  Molecular and biological roles of Ape1 protein in mammalian base excision repair. , 2005, DNA repair.

[3]  M. Kelley,et al.  Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Sophia T. Mundle,et al.  Enzymatic mechanism of human apurinic/apyrimidinic endonuclease against a THF AP site model substrate , 2009, Biochemistry.

[5]  Chang Ming Li,et al.  Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[6]  L. Thompson,et al.  Life without DNA repair. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Kelley,et al.  The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. , 1997, Anticancer research.

[8]  M. Kelley,et al.  The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. , 2007, Molecular aspects of medicine.

[9]  Alessandro Pedretti,et al.  VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. , 2002, Journal of molecular graphics & modelling.

[10]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[11]  M. Berger,et al.  Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  B. Demple,et al.  Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kelley,et al.  Histology-Specific Expression of a DNA Repair Protein in Pediatric Rhabdomyosarcomas , 2001, Journal of pediatric hematology/oncology.

[14]  Richard J Smeyne,et al.  The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[16]  K. Bhakat,et al.  Intracellular trafficking and regulation of mammalian AP-endonuclease 1 (APE1), an essential DNA repair protein. , 2007, DNA repair.

[17]  S. Madhusudan,et al.  Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. , 2010, Cancer treatment reviews.

[18]  I. Hickson,et al.  Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. , 2001, International journal of radiation oncology, biology, physics.

[19]  J. Silber,et al.  Synthesis and characterization of DNA minor groove binding alkylating agents. , 2013, Chemical research in toxicology.

[20]  J. Tainer,et al.  The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra‐helical deoxyribose at DNA abasic sites , 1997, The EMBO journal.

[21]  David M. Wilson,et al.  Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. , 2012, Journal of medicinal chemistry.

[22]  Lirong Wang,et al.  Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. , 2012, Biochemistry.

[23]  David M. Wilson,et al.  Impairment of APE1 Function Enhances Cellular Sensitivity to Clinically Relevant Alkylators and Antimetabolites , 2009, Molecular Cancer Research.

[24]  Ajay N. Jain.  Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities , 1996, J. Comput. Aided Mol. Des..

[25]  T. Lindahl.  Repair of intrinsic DNA lesions. , 1990, Mutation research.

[26]  S. Fox,et al.  Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. , 1998, British Journal of Cancer.

[27]  David M. Wilson,et al.  Identification and Characterization of Inhibitors of Human Apurinic/apyrimidinic Endonuclease APE1 , 2009, PloS one.

[28]  T. Lindahl,et al.  Rate of depurination of native deoxyribonucleic acid. , 1972, Biochemistry.

[29]  M. Sternberg,et al.  Isolation of a small molecule inhibitor of DNA base excision repair , 2005, Nucleic acids research.

[30]  L. Dekker,et al.  Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines , 2011, British Journal of Cancer.

[31]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[32]  Peng Yang,et al.  Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs , 2014, J. Chem. Inf. Model..

[33]  R. S. Coleman,et al.  Effect of protein binding on ultrafast DNA dynamics: characterization of a DNA:APE1 complex. , 2005, Biophysical journal.

[34]  J. Stivers,et al.  Potent Inhibition of Human Apurinic/Apyrimidinic Endonuclease 1 by Arylstibonic Acids , 2008, Molecular Pharmacology.

[35]  M. Kelley,et al.  Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. , 2004, Anticancer research.

[36]  John E. Stone,et al.  Using VMD: An Introductory Tutorial , 2008, Current protocols in bioinformatics.

[37]  K. Wilson,et al.  Crystal structure and DNA repair activities of the AP endonuclease from Leishmania major. , 2007, Journal of molecular biology.

[38]  S. Mitra,et al.  Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells , 2008, Cell Research.

[39]  Chen-Hsiang Yeang,et al.  An integrated analysis of molecular aberrations in NCI-60 cell lines , 2010, BMC Bioinformatics.

[40]  L. Loeb,et al.  Mutagenesis by apurinic/apyrimidinic sites. , 1986, Annual review of genetics.

[41]  Jan H. Jensen,et al.  Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. , 2011, Journal of chemical theory and computation.

[42]  M. Kelley,et al.  Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). , 2010, Journal of medicinal chemistry.

[43]  A. Maitra,et al.  Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration , 2008, Molecular Cancer Therapeutics.

[44]  Ramu Anandakrishnan,et al.  H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations , 2012, Nucleic Acids Res..

[45]  Chen-Hsiang Yeang,et al.  Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines , 2011, BMC Systems Biology.

[46]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[47]  M. Tomicic,et al.  APE/Ref-1 and the mammalian response to genotoxic stress. , 2003, Toxicology.

[48]  Gagandeep Kaur,et al.  DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development. , 2014, Journal of medicinal chemistry.

[49]  J. Hendry,et al.  Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. , 1998, British Journal of Cancer.

[50]  J. Tainer,et al.  DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination , 2000, Nature.

[51]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[52]  R. Dayam,et al.  Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. , 2009, Journal of medicinal chemistry.

[53]  B. Gold,et al.  Groove- and sequence-selective alkylation of DNA by sulfonate esters tethered to lexitropsins. , 1993, Biochemistry.

[54]  G. Garçon,et al.  Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor , 2013, Oncotarget.

[55]  Yun-Jeong Kim,et al.  Overview of base excision repair biochemistry. , 2012, Current molecular pharmacology.

[56]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .